Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Study to Evaluate the Extended Overall Survival From PARSIFAL Trial: Efficacy and Safety of Palbociclib in Combination With Fulvestrant or Letrozole in Patient With HER2-/ER+ Metastatic Breast Cancer (The PARSIFAL-LONG Study)

NCT06525675 is registered in ClinicalTrials.gov with MedSIR as lead sponsor.

NCT NCT06525675
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06525675 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Study to Evaluate the Extended Overall Survival From PARSIFAL Trial: Efficacy and Safety of Palbociclib in Combination With Fulvestrant or Letrozole in Patient With HER2-/ER+ Metastatic Breast Cancer (The PARSIFAL-LONG Study)
Lead sponsor
MedSIR
Phase
Observational
Overall status
Completed
Start date
July 18, 2022
Completion date
September 2, 2024
Enrollment
419 (actual)
Sites
36

Conditions

As the registry lists them; a condition with its own page is linked.

advanced breast cancer, er-positive breast cancer, her2-negative breast cancer, luminal breast cancer, metastatic breast cancer